PharmaNutra consolidated interim report on 30th June 2020

PharmaNutra S.p.A. informs that the Board of Directors has examined and approved the consolidated interim report on 30^th June 2020, drawn up in accordance with the Issuers’ Regulations AIM Italia/Alternative Capital Market and in conformity with the international accounting principles IFRS. The turnover growth trend continues with a leap forward in margins and profits thanks to the Group’s market success, boosting its position in foreign Countries and sales volumes in Italy.

€29.1 M revenue from sales (+17% compared to 30/06/2019)
€9.4 M EBITDA Restated (+49% compared to 30/06/2019)
€6.6 M net income for the period net of the non-recurring item (+65% compared to 30/06/2019)
Positive net financial position of €13.1 M

Andrea Lacorte, President of PharmaNutra S.p.A., commented: “Results achieved in the first half of the year are highly comforting. Regardless of the pharmaceutical market downturn caused by the pandemic, the PharmaNutra figures and trends are still positive and growing. At both scientific and economic level. Of all the acknowledgements received, the fact that PharmaNutra continues to climb the ranks of the more than 1800 nutraceutical companies on the national market, calculated on sales figures to the public, is important. Thanks to a solid financial structure and its current market position, we can, without delay, carry on expanding our business with a highly positive view of the future”.

Roberto Lacorte, Vice President of PharmaNutra S.p.A., added: “These results, together with ongoing investments in the areas of sales, scientific research and human resources, further strengthen the prospects for the long-term strategic development of the Group. While commenting the positive first semester figures, we are still implementing our growing plan whose goal will always be to expand the distribution network, develop new products, take root in some strategic countries directly. The supplements and topicals markets have great growth margins in Italy and abroad. Our daily work is to grasp any opportunity to consolidate and increase PharmaNutra success at global level”.

The consolidated interim financial statement as of 30^th June 2020 will be made available to the public according to the terms and methods envisaged by the Issuer Regulations AIM Italia, as well as on the internet site of PharmaNutra Spa www.pharmanutra.it in the section “Investor Relations”.

Monday 14ᵗʰ September, at 18:00 CET the consolidated interim financial statement will be presented by the Management to analysts and institutional investors.
Click here to read the complete Press Release and the Group accounting prospectus.